The following items discuss clinical research and treatment using cyclophosphamide. For items related to general discussion of clinical research, click here.
Letter discussing a patient with myelomatosis. The patient had myelomatosis since June 1976 and had been in the 3rd MRC trial. Galton discusses treating the patient with weekly cyclophosphamide. Note: contains only page 1 of the letter; missing remaining page(s).
Letter in which Galton reviews Brandes’ manuscript before Brandes submits it for publication to the Lancet. Galton offers feedback and advice on publishing in the Lancet, and discusses a current patient’s course of treatment with cyclophosphamide.
Letter discussing the course of treatment for a patient, alias Mr. Doe, following a recent chest infection.
Letter providing notes on the treatment of a 51-year-old patient from the MRC 3rd trial, including detailed information on dosage and schedule. At the end, Galton provides a brief update on the case of another patient, alias Mr. Doe, whose back was irradiated.
Letter providing an update on a patient with myeloma, alias Mr. Doe, whose disease had rapidly become highly aggressive. Weekly cyclophosphamide and prednisolone were no longer working, and Galton was giving him diamorphine for the pain, while considering treating Mr. Doe with interferon.
Letter providing an update on a patient, alias Mr. Doe, who had died within the last week. Galton provides Mr. Doe’s serum calcium, urea, and creatinine values for July and October.
Letter discussing miscellaneous topics, including publishing in the Lancet, the MRC trial, and a patient Galton intends to start on the Brandes regimen.